Cirrhosis/Liver Failure News

BOSTON — Oral naltrexone 50 mg safely improved alcohol use-related parameters and decompensation, and also reduced cravings, over 1 year among patients with alcohol use disorder and compensated cirrhosis, according to a presenter.

BOSTON — Treatment with TERN-501, a selective thyroid hormone receptor beta agonist, reduced liver fat content and fibro-inflammation among patients with presumed metabolic dysfunction-associated steatohepatitis, late-breaking data showed.

BOSTON — An educational program for transplant nurse coordinators did not improve advanced care planning among patients with decompensated cirrhosis, suggesting that provider training alone is “insufficient” to create significant change.

Patients with acute-on-chronic liver failure and recompensated cirrhosis had less severe disease, lower incidence of respiratory failure and better prognosis at 1 year vs. those with decompensated cirrhosis, researchers reported.

VANCOUVER, British Columbia — Substituting just one meat-based meal with protein from plant or dairy sources could improve metabolite signatures linked to hepatic encephalopathy in patients with cirrhosis, according to a presenter here.

VANCOUVER, British Columbia — Pain was reported in nearly 80% of patients with cirrhosis evaluated for liver transplant and, when paired with anxiety and depression, was a significant driver for poor quality of life, noted a presenter here.

Elevated serum triglyceride levels were associated with severity of acute pancreatitis and risk for related complications, including organ failure, among patients with nonalcoholic fatty liver disease, according to data.

Researchers reported low rifaximin treatment retention among patients with hepatic encephalopathy, with 30-day out-of-pocket treatment costs in excess of $150 among the factors associated with poor adherence.

After nearly a decade of health problems, Steve Harwell, former lead singer and frontman for the band Smash Mouth, died Sept. 4 at age 56, which the band’s manager, Robert Hayes, said was caused by acute liver failure.

Novo Nordisk has awarded a $9.57 million grant supporting a clinical trial at the University of California San Diego NAFLD Research Center to evaluate the use of semaglutide in patients with fibrosis due to nonalcoholic fatty liver disease.